1596 related articles for article (PubMed ID: 30510550)
41. L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice.
Hong H; Brown CE; Ostberg JR; Priceman SJ; Chang WC; Weng L; Lin P; Wakabayashi MT; Jensen MC; Forman SJ
PLoS One; 2016; 11(1):e0146885. PubMed ID: 26761817
[TBL] [Abstract][Full Text] [Related]
42. Prospects of chimeric antigen receptor T cell therapy in ovarian cancer.
Jindal V; Arora E; Gupta S; Lal A; Masab M; Potdar R
Med Oncol; 2018 Apr; 35(5):70. PubMed ID: 29651744
[TBL] [Abstract][Full Text] [Related]
43. T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope.
Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Kruis W; Pohl C; Abken H
Gastroenterology; 1997 Oct; 113(4):1163-70. PubMed ID: 9322511
[TBL] [Abstract][Full Text] [Related]
44. Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells.
Starr R; Aguilar B; Gumber D; Maker M; Huard S; Wang D; Chang WC; Brito A; Chiu V; Ostberg JR; Badie B; Forman SJ; Alizadeh D; Wang LD; Brown CE
Cancer Res Commun; 2023 Jan; 3(1):66-79. PubMed ID: 36968221
[TBL] [Abstract][Full Text] [Related]
45. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.
Salter AI; Ivey RG; Kennedy JJ; Voillet V; Rajan A; Alderman EJ; Voytovich UJ; Lin C; Sommermeyer D; Liu L; Whiteaker JR; Gottardo R; Paulovich AG; Riddell SR
Sci Signal; 2018 Aug; 11(544):. PubMed ID: 30131370
[TBL] [Abstract][Full Text] [Related]
46. Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.
Balakrishnan A; Rajan A; Salter AI; Kosasih PL; Wu Q; Voutsinas J; Jensen MC; Plückthun A; Riddell SR
Clin Cancer Res; 2019 Dec; 25(24):7506-7516. PubMed ID: 31548346
[TBL] [Abstract][Full Text] [Related]
47. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.
Walker AJ; Majzner RG; Zhang L; Wanhainen K; Long AH; Nguyen SM; Lopomo P; Vigny M; Fry TJ; Orentas RJ; Mackall CL
Mol Ther; 2017 Sep; 25(9):2189-2201. PubMed ID: 28676342
[TBL] [Abstract][Full Text] [Related]
48. Armed with IL-2 based fusion protein improves CAR-T cell fitness and efficacy against solid tumors.
Li S; Xia Y; Hou R; Wang X; Zhao X; Guan Z; Ma W; Xu Y; Zhang W; Liu D; Zheng J; Shi M
Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167159. PubMed ID: 38583815
[TBL] [Abstract][Full Text] [Related]
49. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
[TBL] [Abstract][Full Text] [Related]
50. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
51. Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor.
Schutsky K; Song DG; Lynn R; Smith JB; Poussin M; Figini M; Zhao Y; Powell DJ
Oncotarget; 2015 Oct; 6(30):28911-28. PubMed ID: 26359629
[TBL] [Abstract][Full Text] [Related]
52. Use of a Single CAR T Cell and Several Bispecific Adapters Facilitates Eradication of Multiple Antigenically Different Solid Tumors.
Lee YG; Marks I; Srinivasarao M; Kanduluru AK; Mahalingam SM; Liu X; Chu H; Low PS
Cancer Res; 2019 Jan; 79(2):387-396. PubMed ID: 30482775
[TBL] [Abstract][Full Text] [Related]
53. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies.
Mamonkin M; Mukherjee M; Srinivasan M; Sharma S; Gomes-Silva D; Mo F; Krenciute G; Orange JS; Brenner MK
Cancer Immunol Res; 2018 Jan; 6(1):47-58. PubMed ID: 29079655
[TBL] [Abstract][Full Text] [Related]
54. NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer.
Li J; Hu H; Lian H; Yang S; Liu M; He J; Cao B; Chen D; Hu Y; Zhi C; Shen Y; Ye X; He B; Zhao M; Fan W; Xu L; Leidner R; Wu Q; Yang L; Zhang Z
Int J Biol Sci; 2024; 20(5):1578-1601. PubMed ID: 38481806
[No Abstract] [Full Text] [Related]
55. Prospects and challenges of CAR-T in the treatment of ovarian cancer.
Chen B; Liu J
Int Immunopharmacol; 2024 May; 133():112112. PubMed ID: 38640714
[TBL] [Abstract][Full Text] [Related]
56. TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors.
Nishimura CD; Corrigan D; Zheng XY; Galbo PM; Wang S; Liu Y; Wei Y; Suo L; Cui W; Mercado N; Zheng D; Zhang CC; Zang X
Sci Adv; 2024 May; 10(19):eadk1857. PubMed ID: 38718110
[TBL] [Abstract][Full Text] [Related]
57. CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors.
Chen H; Wei F; Yin M; Zhao Q; Liu Z; Yu B; Huang Z
Cancer Immunol Immunother; 2021 Jul; 70(7):2059-2071. PubMed ID: 33439295
[TBL] [Abstract][Full Text] [Related]
58. Dual CAR-T cells to treat cancers co-expressing NKG2D and PD1 ligands in xenograft models of peritoneal metastasis.
Jiang G; Ng YY; Tay JCK; Du Z; Xiao L; Wang S; Zhu J
Cancer Immunol Immunother; 2023 Jan; 72(1):223-234. PubMed ID: 35809118
[TBL] [Abstract][Full Text] [Related]
59. Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.
Weimin S; Abula A; Qianghong D; Wenguang W
Cancer Biol Ther; 2020 Jun; 21(6):570-580. PubMed ID: 32208880
[No Abstract] [Full Text] [Related]
60. Making CAR T Cells a Solid Option for Solid Tumors.
Schmidts A; Maus MV
Front Immunol; 2018; 9():2593. PubMed ID: 30467505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
